Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 803-815
Closed Access | Times Cited: 308

Showing 1-25 of 308 citing articles:

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 305
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 190
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 126
Current and emerging therapies for advanced biliary tract cancers
Audrey E. Kam, Ashiq Masood, Rachna T. Shroff
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 956-969
Closed Access | Times Cited: 116
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 87
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 56-65
Closed Access | Times Cited: 84
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 65
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
James J. Harding, Sarina A. Piha‐Paul, Ronak Shah, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 49
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 43
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 42
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 21
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Zhipeng Cao, Sadia Quazi, Sakshi Arora, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 4
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 11, pp. 2270-2277
Open Access | Times Cited: 66
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 50
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Olaf Neumann, Timothy C. Burn, Michael Allgäuer, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 8, pp. 1540-1549
Open Access | Times Cited: 40
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 33
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 31
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma
Shishir K. Maithel, Jessica M. Keilson, Hop S. Tran Cao, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 11, pp. 6558-6566
Closed Access | Times Cited: 30
Clinical development and management of adverse events associated with FGFR inhibitors
Vivek Subbiah, Srđan Verstovšek
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101204-101204
Open Access | Times Cited: 28
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
Changhoon Yoo, Milind Javle, Helena Verdaguer Mata, et al.
Hepatology (2023)
Open Access | Times Cited: 26
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 24
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top